Browse by author
Lookup NU author(s): Dr Fiona Shrive, Professor Cam Donaldson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Restenosis is a major limitation to the long-term success of percutaneous coronary intervention. Drug-eluting stents are the most recent technological advance in restenosis prevention. While they are effective, their use is associated with a significant incremental cost, and a recent economic evaluation performed by the authors suggested that their use is associated with a cost per quality-adjusted life year of $58,721. How should decision-makers react to this value, particularly given that the use of sirolimus-eluting stents appears more attractive in certain patient subgroups, such as those with complex coronary lesions? In the present paper, the authors explore an alternative method of presenting the results of their economic evaluation, rather than the usual cost per quality-adjusted life year rubric, in an attempt to assist decision-makers in deciding whether, and for whom, to fund sitolimus-eluting stents. Several issues that decision-makers and providers may wish to consider when making such funding decisions are discussed. © 2005 Pulsus Group Inc. All rights reserved.
Author(s): Shrive FM, Ghali WA, Lewis S, Donaldson C, Knudtson ML, Manns BJ
Publication type: Article
Publication status: Published
Journal: Canadian Journal of Cardiology
Year: 2005
Volume: 21
Issue: 9
Pages: 783-787
Print publication date: 01/07/2005
ISSN (print): 0828-282X
ISSN (electronic): 1916-7075
Publisher: Pulsus
URL: http://www.pulsus.com/journals/abstract.jsp?sCurrPg=abstract&jnlKy=1&atlKy=893&isuKy=131&isArt=t&fromfold=
PubMed id: 16082437